Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Dan Loeb Goes Activist on Baxter International Inc (BAX) and Asks for Two Seats on the Board

Page 1 of 2

In a new filing with the Securities and Exchange Commission, Dan Loeb‘s Third Point disclosed a large activist stake in Baxter International Inc (NYSE:BAX) and a letter sent to the company’s Chairman and CEO Robert L. Parkinson and lead director Thomas Stallkamp. According to the filing, the investor owns around 37.92 million shares of the company, representing 7% of the outstanding stock. In the letter, Dan Loeb applauded the company’s latest performance and asked to appoint two representatives on the board of directors due to its large economic exposure to the company.


The investor met with Parkinson and Stallkamp last week to discuss the future plans of the company.  Following the addition of Baxter to its equity portfolio, Third Point has become the largest shareholder of the company. Meanwhile, Baxter has done a number of steps that made it more attractive to investors in the last months, such as the spin-off of Baxalta in June. The letter added that Third Point is also pleased with the decision to implement a CEO succession plan and suggested to assist to this process with the addition of its representatives on the board of directors.

“[…] we are most impressed by your willingness to consider new Directors for the Board to compliment the new CEO. Given Third Point’s significant economic exposure – worth over $2 billion – we discussed nominating our representatives for two Board seats.”

Loeb added that Third point has an “excellent track record of participating on corporate boards and CEO search committees.” Due to the friendly nature of the letter and the fact that Third Point held a meeting with the company’s representatives, it’s most likely that Baxter will accept the investor’s proposal and will nominate its nominees on the board.

Meanwhile, the stock of Baxter International Inc (NYSE:BAX) has gained ground lately,  having advanced by 9% in the last week. Year-to-date, the stock inched up by 1.24%, even though it dipped around the spin-off of Baxalta Inc (NYSE:BXLT). Baxalta is Baxter’s former specialty drug-focused arm and it gained around 10% since it went public as an independent company. Yesterday, Shire PLC (ADR) (NASDAQ:SHPG) released a statement in which it said that it had made an offer to acquire Baxalta Inc (NYSE:BXLT) before the spin-off, but Baxter refused to engage in discussions.

Following the spin-off of Baxalta, Baxter International Inc (NYSE:BAX) has been focusing on medical devices and supplies for hospitals. However, the investor considers that its “staggered Board” is “shareholder unfriendly and archaic” due to its voting structure that values shareholders individually.

“We believe most shareholders agree with our views and as it turns out, so do you. We are confident that by working together, we will ensure shareholders can elect all directors at the 2016 annual meeting, including our representatives,” Dan Loeb added.

At the end of last month, Baxter International Inc (NYSE:BAX) announced its financial results for the second quarter of 2015, which included revenue of $3.89 billion, down from $4.15 billion a year earlier, and a 28% annual decline in EPS to $0.62. For the current quarter, the company expects a 3% growth in sales over the year and EPS in the range between $0.29 and $0.31.

The last round of 13F filings showed a significant increase in bullish sentiment from hedge funds, which might grow even further with the involvement of a great activist like Dan Loeb. Overall, 50 funds held long positions in the company at the end of March, with an aggregate value of $1.47 billion, versus 35 funds with $782.39 million worth of stock a quarter earlier. The involvement of an activist generally suggests an increase in shareholder value, which is also supported by stronger return of activists, compared to their passive peers.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!